7 completed, 4 active not recruiting, 2 terminated, 1 recruiting. 9 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 6, Active not recruiting 2, Recruiting 1 |
| Phase 2 | 6 | Active not recruiting 2, Completed 2, Terminated 2 |
Follow danvatirsen: new trials by email Literature Review of danvatirsen trials Research Report on danvatirsen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML Danvatirsen, Danvatirsen + Venetoclax - AML/MDS, Acute Myeloid Leukemia | Phase 1 | Recruiting | Montefiore Medical Center | 38 | 2024-05-08 | 2026-10-15 |
| Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC Danvatirsen, Pembrolizumab - HNSCC | Phase 2 | Terminated | Flamingo Therapeutics NV | 69 | 2023-05-30 | 2026-01-30 |
| Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer Durvalumab, Oleclumab, Monalizumab - Resectable, Early-stage | Phase 2 | Completed | MedImmune LLC | 84 | 2019-03-08 | 2022-02-24 |
| A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC Durvalumab, Danvatirsen, Oleclumab - Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Active not recruiting | AstraZeneca | 175 | 2018-12-27 | 2026-05-12 |
| Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) AZD9150, Acalabrutinib, AZD6738 - NHL, DLBCL | Phase 1 | Completed | Acerta Pharma BV | 30 | 2018-06-19 | 2022-08-15 |
| AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer AZD9150, Durvalumab, Cisplatin - Advanced Solid Tumours | Phase 1 | Completed | AstraZeneca | 76 | 2018-02-07 | 2024-08-21 |
| Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies AZD9150, Durvalumab - Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 11 | 2018-01-30 | 2019-06-24 |
| Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy Durvalumab, Danvatirsen, Ceralasertib - Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | AstraZeneca | 528 | 2017-12-18 | 2025-10-27 |
| Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer Danvatirsen, Durvalumab - Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 39 | 2017-03-02 | 2025-05-06 |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer AZD4547, MEDI4736, Olaparib - Muscle Invasive Bladder Cancer | Phase 1 | Active not recruiting | AstraZeneca | 117 | 2016-12-28 | 2026-10-01 |
| MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) MEDI4736, tremelimumab, AZD9150 - Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | MedImmune LLC | 32 | 2016-07-13 | 2019-02-27 |
| Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck AZD9150, MEDI4736, AZD5069 - Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck | Phase 1 / Phase 2 | Completed | AstraZeneca | 340 | 2015-08-06 | 2026-02-11 |
| AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites AZD9150 - Ovarian Cancer, Ovarian Neoplasms | Phase 2 | Terminated | National Cancer Institute (NCI) | 1 | 2015-04-03 | 2017-05-15 |
| A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma AZD9150 - Advanced Adult Hepatocellular Carcinoma, Hepatocellular Carcinoma Metastatic | Phase 1 | Completed | AstraZeneca | 58 | 2013-05-01 | 2017-03-06 |
Carcinoma, Non-Small-Cell Lung (4) · Lymphoma, Large B-Cell, Diffuse (2) · Ascites (1) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Lung Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic Syndromes (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Turcot syndrome (1)
AstraZeneca (7) · MedImmune LLC (2) · Acerta Pharma BV (1) · Flamingo Therapeutics NV (1) · M.D. Anderson Cancer Center (1) · Montefiore Medical Center (1) · National Cancer Institute (NCI) (1)
United States (12) · Spain (5) · United Kingdom (5) · France (4) · South Korea (4) · Canada (3) · Austria (2) · Belgium (2) · Germany (2) · Italy (2) · Japan (2) · Taiwan (2) · Hong Kong (1) · Ireland (1) · Israel (1)
Aditi Shastri, MBBS (1) · Chih-Hsin Yang, MD (1) · David S Hong (1) · Dr David Hong, MD (1) · Frank Neumann, MD (1) · Hendrik-Tobias Arkenau, MD, PhD (1) · Ian Flinn, MD, PhD (1) · John Heymach, M.D, Ph.D (1) · Melissa Johnson, M.D. (1) · Nabil Saba, MD (1) · Sandip Patel, MD (1) · Thomas Powles, MBBS, MRCP, MD (1) · Tim F Greten, M.D. (1)
PMID 32203306, PMID 36270753, PMID 37707791, PMID 38351187, PMID 39886125, PMID 41380462
2017 (3), 2015 (2), 2018 (1), 2023 (1)